These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10268557)

  • 1. The Yale algorithm. Special workshop--clinical.
    Kramer MS; Hutchinson TA
    Drug Inf J; 1984; 18(3-4):283-91. PubMed ID: 10268557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A quantitative approach of using genetic algorithm in designing a probability scoring system of an adverse drug reaction assessment system.
    Koh Y; Yap CW; Li SC
    Int J Med Inform; 2008 Jun; 77(6):421-30. PubMed ID: 17921048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use.
    Kramer MS; Leventhal JM; Hutchinson TA; Feinstein AR
    JAMA; 1979 Aug; 242(7):623-32. PubMed ID: 449002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Food and Drug Administration algorithm. Special workshop--regulatory.
    Turner WM
    Drug Inf J; 1984; 18(3-4):259-66. PubMed ID: 10268553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. False-positives in spontaneous reporting: should we worry about them?
    Begaud B; Moride Y; Tubert-Bitter P; Chaslerie A; Haramburu F
    Br J Clin Pharmacol; 1994 Nov; 38(5):401-4. PubMed ID: 7893579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standardized assessment of adverse drug reactions: the method used in France. Special workshop--clinical.
    Begaud B
    Drug Inf J; 1984; 18(3-4):275-81. PubMed ID: 10268556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Australian method of drug-event assessment. Special workshop--regulatory.
    Mashford ML
    Drug Inf J; 1984; 18(3-4):271-3. PubMed ID: 10268555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Swedish drug-event assessment methods. Special workshop--regulatory.
    Wiholm BE
    Drug Inf J; 1984; 18(3-4):267-9. PubMed ID: 10268554
    [No Abstract]   [Full Text] [Related]  

  • 9. A primer of drug safety surveillance: an industry perspective. Part II: Product labeling and product knowledge.
    Allan MC
    J Pharm Technol; 1992; 8(5):198-202. PubMed ID: 10171208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postmarketing surveillance of adverse drug reactions: problems and solutions.
    Lortie FM
    CMAJ; 1986 Jul; 135(1):27-32. PubMed ID: 3719483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Legal perspectives in causality assessment.
    Freilich WB
    Drug Inf J; 1984; 18(3-4):211-7. PubMed ID: 10268552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspects of standardization as applied to the assessment of drug-event associations.
    Venulet J
    Drug Inf J; 1984; 18(3-4):199-210. PubMed ID: 10268551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Difficulties in assessing the adverse effects of drugs.
    Kramer MS
    Br J Clin Pharmacol; 1981; 11 Suppl 1(Suppl 1):105S-110S. PubMed ID: 7052788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postmarketing surveillance for drug safety.
    Holden WL; Scarazzini LJ
    Clin Pharmacol Ther; 2004 Nov; 76(5):503; author reply 504-5. PubMed ID: 15536464
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug related hospital admissions in subspecialities of internal medicine.
    Hallas J
    Dan Med Bull; 1996 Apr; 43(2):141-55. PubMed ID: 8741207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving the Food and Drug Administration's mandate to ensure postmarketing drug safety.
    Qato DM; Alexander GC
    JAMA; 2011 Oct; 306(14):1595-6. PubMed ID: 21990303
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts.
    Pierce CE; Bouri K; Pamer C; Proestel S; Rodriguez HW; Van Le H; Freifeld CC; Brownstein JS; Walderhaug M; Edwards IR; Dasgupta N
    Drug Saf; 2017 Apr; 40(4):317-331. PubMed ID: 28044249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes.
    Hoffman KB; Dimbil M; Kyle RF; Tatonetti NP; Erdman CB; Demakas A; Chen D; Overstreet BM
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1134-43. PubMed ID: 26679963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can causality assessment fulfill the new European definition of adverse drug reaction? A review of methods used in spontaneous reporting.
    Mascolo A; Scavone C; Sessa M; di Mauro G; Cimmaruta D; Orlando V; Rossi F; Sportiello L; Capuano A
    Pharmacol Res; 2017 Sep; 123():122-129. PubMed ID: 28694146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A questionnaire for the clinical assessment of veterinary adverse drug reactions.
    Hoskins JD; Hubbert WT; Selig JO
    Cornell Vet; 1982 Jan; 72(1):3-15. PubMed ID: 7067454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.